MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan

MyMD | November 24, 2021

MyMD Pharmaceuticals
MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual.

This patent is a timely addition to our IP portfolio as we advance toward the launch of our fully funded Phase 2 trial of MYMD-1 for aging. After a comprehensive review by USPTO, we are pleased with the broad scope of the granted claims which offer further protection for our lead drug candidate, which we believe has the potential to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging healthy lifespan,” 

 Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD

“Our primary focus for MYMD-1 is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan,” Dr. Chapman added. “It’s also important to note that MYMD-1 shows promise in pre-clinical studies as a treatment for immune diseases including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, and as an anti-fibrotic and anti-proliferation therapeutic.”

The latest patent adds to MyMD’s intellectual property portfolio of 14 granted patents (12 U.S. and two foreign) covering MYMD-1 in methods of treating chronic inflammation, autoimmune disorders, diabetes, multiple sclerosis, viral infections, addictions, fibrosis, asthma, and other disorders. MyMD also holds two patents for its synthetic cannabidiol (CBD) derivative Supera-CBD. An additional 30 patent applications are pending worldwide.

About MYMD-1
Originally developed for autoimmune diseases, MYMD-1’s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Its mechanism of action and efficacy in diseases including multiple sclerosis (MS) and thyroiditis have been studied through collaborations with several academic institutions. MYMD-1 is also showing promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation.

About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.


To meet your requirements even better, we have created a specific range of drug delivery technologies, EUDRATEC. For both EUDRAGIT and EUDRATEC we offer tailor-made development services for commercially viable formulations. We develop and manufacture clinical trial formulations for biologics and small molecules according to your requirements, also including Highly Potent Active Pharmaceutical Ingredients (HPAPIs).


To meet your requirements even better, we have created a specific range of drug delivery technologies, EUDRATEC. For both EUDRAGIT and EUDRATEC we offer tailor-made development services for commercially viable formulations. We develop and manufacture clinical trial formulations for biologics and small molecules according to your requirements, also including Highly Potent Active Pharmaceutical Ingredients (HPAPIs).

Related News


Biomind Labs Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing

Biomind Labs | November 25, 2021

Biomind Labs Inc. a leading biotech company in fast-acting psychedelics is pleased to announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various inflammatory disorders. “We believe we are the first company in the world to design a pharmaceutical form for psychedelic drug delivery using 3D printing. This paramount step in our rapid evolution towards becoming a pharmaceutical company, was achieved by our team of scientists who have designed a novel pharmaceutical form to be used with our psychedelic candidates. We are very proud of how our research and development division advances in the development of complex products, on-demand products, and customized products, aimed to address a wide range of needs from patients with different mental health conditions. 3D printing allows creating three-dimensional objects layer by layer, thereby achieving products with variable geometries. Inside the universe of pharmaceutical technology, 3D printing allows combining of shapes and stratification of materials; thus, possibly controlling the time and place of drug release. One of the most interesting and potentially exciting results is that doses can be adjusted in real time for the specific needs of each patient. 3D printing of psychedelics could be key to the future of the industry, not just because it allows us to personalize medicine but also for creating sustainable production, while reducing the environmental burden”, commented Alejandro Antalich, CEO of Biomind Labs. About Biomind Labs Inc. Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments and use cases.

Read More


Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France

Humanigen and Cenexi | February 09, 2022

France Humanigen, Inc. a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Cenexi, a French CDMO specializing in the formulation, analytical development, and manufacture of complex molecule drugs, announced a collaboration aimed at making Cenexi a preferred supplier of lenzilumab in France and the European Union. The initial step of the collaboration includes the execution of a Master Supply Agreement (“MSA”) providing for Cenexi to provide aseptic fill and finish services for lenzilumab for the next five years. Under the terms of the agreement, Humanigen will transfer the technology and knowledge to Cenexi to allow them to establish drug product processes utilizing their state-of-the-art high speed filling line at their Herouville-Saint-Clair facility in Normandy. Humanigen and Cenexi will enter into discussions to potentially expand the agreement to other services Cenexi offers. These include labeling and packaging, importation of bulk drug substance and quality release of materials in France and throughout Europe. Humanigen plans to include the Cenexi Normandy site in certain of its future regulatory filings for lenzilumab for COVID-19 and other indications. The companies will collaborate to secure potential funding and investment in capital equipment from AD Normandie, the regional authority and the Government of France, the national authority. In addition, Cenexi will assist Humanigen as it seeks an advanced purchase agreement for lenzilumab in France. “The goal of the collaboration with Cenexi is to further our efforts to establish a supply of lenzilumab made in Europe. Cenexi is an ideal partner for sterile filling and with their strong base of resources and aggressive growth plan, we may expand our collaboration beyond the typical customer/vendor relationship. We may work with Cenexi to become our preferred partner for multiple services and to establish a stable and secure supply chain for lenzilumab in France and Europe longer-term.” Cameron Durrant, chief executive officer of Humanigen In 2021, French authorities modified existing regulations to provide for early access to unauthorized medicinal products. The early access authorization allows for a manufacturer to supply product to a cohort of individuals for a specific use, for example, lenzilumab for COVID-19. Humanigen plans to file a request for AAP with the Haute Authorite de Sante in February 2022. “Cenexi desires a leadership position in France to assist in establishing a strong supply chain for COVID-19 and for future pandemics. Since 2004, Cenexi has been at the forefront of bringing critical medicines to patients and we continue to build on our strong reputation for value, high quality, flexibility and timeliness,” commented Christophe Durand, chief executive officer of Cenexi. “Our partnership with Humanigen will use our core competencies of sterile filling and to potentially expand into to an end-to-end solution for lenzilumab in France and other countries in Europe.” Pending positive results from the NIH-sponsored ACTIV-5/BET-B study, Humanigen plans to amend the Emergency Use Authorization application in the United States. For the European Union, Humanigen anticipates submission of a Conditional Marketing Authorization with a request for Accelerated Approval in the third quarter of 2022. Lenzilumab is an investigational product and is not approved or authorized in any country. About Humanigen Humanigen, Inc. is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. In addition, Humanigen is progressing a Phase 1 program focused on another proprietary monoclonal antibody, ifabotuzumab, in solid tumors. About Cenexi Cenexi, a major French CDMO operating in Europe with 1,500 employees and some €200 million in turnover (2021), is experiencing steady growth with four production sites and a center of expertise dedicated to new product introduction.

Read More


Thermo Fisher sketches out Carlsbad plasmid DNA plant as German cell and gene therapy facility preps for opening

Thermo Fisher | December 23, 2020

Thermo Fisher Scientific is shoring up production of cell and quality treatments on the two sides of the lake, a move it expectations will support the advancement of COVID-19 medications and antibodies—and guarantee supplies are set up should they get by with controllers. The New Jersey contract producer is spreading out another plasmid DNA fabricating office at its Carlsbad, California, grounds, intending to help its phone and quality treatment contributions against the setting of a worldwide plasmid market where request has immediately dominated supply, the organization said. That is on top of plans for another cryocenter in Germany. That webpage, one of two new German offices set to come online in the following not many weeks, will offer virus chain support for clinical preliminaries of cell and quality treatments, including COVID-19 immunization hopefuls, in Europe and past. The 67,000-square-foot Carlsbad office will add exactly 150 positions throughout the following a year, with development fixed to enclose by the principal half of 2021, Thermo Fisher said. The site will support clinical and business yield of plasmid DNA used to create and deliver cell and quality treatments for disease, just as mRNA immunizations. It will likewise be prepared to produce huge scope plasmid DNA as an essential medication substance for DNA treatments, the organization said. The office will be kitted out with single-utilize hardware equipped for taking care of undertakings up to 1,000 liters and will flaunt computerized network and information visibility to smooth activities and make preparing representatives simpler, Thermo Fisher said. Thermo Fisher is no more abnormal to the field, with a phone and quality treatment impression in Massachusetts and Florida, in addition to a recently stamped cell treatment producing plant in Princeton, New Jersey—however it calculates the extended business and supply chain administrations at its Carlsbad site will smooth the wrinkles in the current plasmid market. "The competition to grow new groundbreaking cell and quality treatments and antibodies is outperforming supply of business quality plasmid DNA that can be created at scale," Mike Shafer, SVP and leader of pharma administrations at Thermo Fisher, said in a delivery. "Our new cutting edge site won't just handle the supply bottleneck for our clients yet in addition particularly positions us to convey powerful, start to finish cell and quality treatment capacities."

Read More